Pribacapsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
AhnGuk New Pharm Co., Ltd.
MFDS item code 201906644 · Approved 2019.09.23
This product's status changed to Expired on 2024.09.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia
This medication is used in adults for the treatment of peripheral and central neuropathic pain. It is also used as an adjunct for partial seizures in epilepsy, applicable whether or not secondary generalized symptoms are present. Furthermore, it is effective in the treatment of fibromyalgia. In other words, this drug is used to improve neuropathic pain, partial seizures in epilepsy, and fibromyalgia.
This medication is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin: initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin: initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin: initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if any symptoms of depression or mood changes occur during treatment, patients should immediately inform their healthcare provider. Patients with allergies to any components of this medication or those with certain genetic issues such as lactose intolerance should not take it. Diabetic patients may experience weight gain from this medication, which may require dosage adjustment of blood sugar control medications. If symptoms of angioedema occur, such as swelling around the face or mouth, the use of this medication should be stopped immediately. Elderly patients should be cautious as the risk of dizziness or drowsiness may increase, and symptoms like loss of consciousness or confusion may occur. Some patients may temporarily experience blurred vision or other visual changes, and these symptoms may improve upon discontinuation of the medication. Abruptly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so the dosage should be tapered gradually with medical consultation. Patients with a history of substance abuse may have an increased risk of misuse of this medication, so special caution is advised during use. Patients with decreased kidney function may require dose adjustments for this medication. Patients with heart conditions should consult their doctor before taking this medication and should use it cautiously if they have severe heart failure. Using this medication in conjunction with opioid analgesics may increase the risk of central nervous system depression, so strict adherence to the prescriber's instructions is necessary. In patients with respiratory or neurological diseases or those who are elderly, the risk of severe respiratory depression may necessitate dose adjustments. This medication is not recommended for pregnant women in early pregnancy due to the risk of congenital defects in the fetus, and women of childbearing potential should use effective contraceptive methods. Breastfeeding women should consult their healthcare provider regarding the use of this medication, as it can be transmitted in breast milk. This medication can cause dizziness and drowsiness, so patients should confirm their conditions before driving or operating machinery. Rarely, serious allergic reactions may occur on the skin; if symptoms like rash, swelling, or shortness of breath appear, the medication should be stopped immediately and a healthcare provider notified. In case of overdose, symptoms like drowsiness, confusion, or depression may appear, and treatments such as hemodialysis may be required if necessary. This medication should be kept out of reach of children and it is advisable to avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
The medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is important to maintain storage temperatures between 15 to 30 degrees Celsius to safely preserve its efficacy.
A white hard capsule containing a white powder that is white or light yellow in color
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Hard capsule · Prescription medication
AhnGuk New Pharm Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.